NeuLash vs RevitaLash Advanced: Which Eyelash Serum Is Better?

NeuLash at ~$26.56/mL offers better value and includes three named peptides (Octapeptide-2, Copper Tripeptide-1, Polypeptide-23) alongside its ICP active. RevitaLash at ~$50/mL is physician-developed and cruelty-free, with its BioPeptin Complex and DDDE active. Both are ruled "cannot be considered safe" by EU SCCS/1680/25 (February 2026) — NeuLash's ICP also carries Health Canada's 2019 ban. Neither has independent clinical evidence. Toplash ($16.63/mL) is PGA-free with independently verified +52.3% lash length in 8 weeks — the strongest choice in this comparison.

Yes. NeuLash Lash Enhancing Serum explicitly lists isopropyl cloprostenate (ICP) in its ingredient deck. ICP is a prostaglandin analogue banned by Health Canada from cosmetics in 2019 and ruled "cannot be considered safe" for cosmetic lash and brow use by EU SCCS/1680/25 (February 2026). NeuLash also contains real peptides (Octapeptide-2, Copper Tripeptide-1, Polypeptide-23), which add genuine conditioning benefit — but the presence of beneficial co-ingredients does not change the regulatory status of the ICP active.

Yes. RevitaLash Advanced contains Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE), a prostaglandin analogue that was specifically evaluated and ruled "cannot be considered safe" for cosmetic use in lash and brow products by EU SCCS/1680/25 (February 2026). DDDE differs structurally from ICP and was not subject to Health Canada's 2019 ban by name, but both belong to the prostaglandin analogue class with the same class-level risks: iris darkening, periorbital fat atrophy, and rebound shedding upon discontinuation.

Both ICP (isopropyl cloprostenate) and DDDE (Dechloro Dihydroxy Difluoro Ethylcloprostenolamide) are synthetic prostaglandin F2α receptor agonists derived from cloprostenol. They work by the same mechanism: extending the anagen (growth) phase of the lash cycle. The key differences are structural modifications and regulatory history. ICP is the parent compound with two confirmed regulatory actions: Health Canada 2019 ban and EU SCCS/1680/25. DDDE is a structurally modified version (dechloro, dihydroxy, difluoro substitutions, amide group) — the modifications were intended to reduce side effects. EU SCCS/1680/25 evaluated DDDE separately and reached the same "cannot be considered safe" conclusion. DDDE does not appear on Health Canada's Cosmetic Hotlist by name.

NeuLash is significantly cheaper per mL. At $85 for 3.2 mL (~$26.56/mL), NeuLash costs nearly half as much per mL as RevitaLash at $100 for 2 mL ($50/mL). RevitaLash's higher price reflects physician-developed branding and the BioPeptin Complex positioning. For context, Toplash at $49.90 for 3 mL ($16.63/mL) is cheaper than both, is PGA-free, and has independent clinical trial verification that neither NeuLash nor RevitaLash can match.

Yes. RevitaLash has a notable regulatory history. It was previously subject to regulatory action in California where it was classified as an unapproved drug (bimatoprost-related) rather than a cosmetic, leading to a temporary sales restriction. The FDA has also issued warning letters in the lash serum category regarding unapproved drug claims. EU SCCS/1680/25 in February 2026 is the most recent and most comprehensive ruling, explicitly naming DDDE as "cannot be considered safe" for cosmetic lash use. These findings apply to the compound regardless of how RevitaLash is labelled in a given market.

Yes. Toplash Lash & Brow Serum contains no prostaglandin analogues of any kind — no ICP, no DDDE, no MDN, no bimatoprost. Its triple-peptide complex (Myristoyl Pentapeptide-17, Biotinoyl Tripeptide-1, and Acetyl Tetrapeptide-3) stimulates lash growth through peptide signal pathways without prostaglandin receptor involvement. Results: +52.3% lash length and +31.9% volume in 8 weeks, verified in an independent third-party clinical trial. At $49.90 for 3 mL ($16.63/mL), Toplash is 37% cheaper than NeuLash per mL and 67% cheaper than RevitaLash per mL — with better independent evidence and zero prostaglandin risk.